Desonide
As of the edition of 20 October 2026, Desonide is a small molecule: marketed, first approved in 1982 (US); acts on NR3C1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Tridesilon
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 3 regions
- Holder of the most recent approval
- Aché Laboratórios Farmacêuticos; 7 holders in all
- Registered trials
- 3, 0 stopped early
- Disease areas
- Immune system; Inherited and neonatal; Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Desonide.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Galderma | Acquired holder | 2003 to now |
| Aché Laboratórios Farmacêuticos | Applicant | 2009 to now |
| LEO Pharma | Acquired holder | 2019 to now |
| Padagis | Acquired holder | 2021 to now |
| Genus Lifesciences | Acquired holder | 2026 to now |
| Bayer | Later holder and Earlier holder |